Carl N. Kraus - 20 Jan 2023 Form 4 Insider Report for Aceragen, Inc.

Reporting relationship: CHIEF MEDICAL OFFICER
Issuer ticker: N/A
Reported as of: 20 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Feb 2023, 19:10:55 UTC
Prior SEC filing: 19 Jan 2023
Next SEC filing: 30 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ John J. Kirby, Attorney-in-Fact

Key filing fact

Carl N. Kraus filed Form 4 for Aceragen, Inc. on 02 Feb 2023.

Key facts

This page summarizes Carl N. Kraus's Form 4 filing for Aceragen, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Feb 2023, 19:10.

Change

Previous filing in this sequence was filed on 19 Jan 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACGN transaction Derivative

Stock Options (Right ot Buy)

Award

Transaction value: $0
Shares: +25,400
Change %
Price: $0.000000
Shares after: 25,400
Date: 20 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,400
Exercise price: $5.21
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option award was granted under the Issuer's 2022 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 20, 2023. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 20, 2024 (first anniversary of the date of grant) and the balance vests in thirty-six equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.